Recently, Beijing Cenglang BioTech Co., Ltd. (hereinafter referred to as "Cenglang BioTech"), a well-known enterprise in China's flow cytometry field, announced the completion of tens of millions of yuan in financing. This round was exclusively invested by Sunshine Harmony Capital, with StarBridge Capital serving as the exclusive financial advisor. Following its financing in March 2024, Cenglang BioTech has once again gained favor from the capital market, highlighting the industry's broad recognition of domestic high-end flow cytometry technology innovation capabilities and commercialization prospects.

Industry Breakthrough: Domestic Substitution of High-End Flow Cytometry is Imperative

The U.S. Department of Commerce’s "High-Parameter Flow Cytometry Export Ban," effective January 16, 2025, has caused significant shockwaves throughout the flow cytometry industry. The ban prohibits the export to China of flow cytometry products with "26 channels or more," "full spectrum," and "sorting-type" specifications. This has had a considerable impact on the development of life sciences in China, but also presents a major opportunity for domestic flow cytometry.

Flow cytometers, serving as the "Cell CT" in life science research and clinical diagnostics, are widely used in cutting-edge fields such as immune function assessment, hematological disease diagnosis, and tumor immunotherapy monitoring. For a long time, the global market has been dominated by international brands, with high-end models being expensive and protected by high core technology barriers, severely constraining the autonomy of China’s life science research and precision medicine development.

Data shows that in 2025, China’s flow cytometry market size exceeded RMB 6 billion, with a compound annual growth rate of over 15%. Demand for high-end models accounts for more than 60% of the market, but domestic equipment market share is less than 20%, concentrated mainly in the mid-to-low-end segments (Data source: Comprehensive calculations based on industry analysis reports from ChinaIRN.com and Newsijie.com). With the "15th Five-Year Plan" promoting the domestic substitution of life sciences and high-end medical devices, coupled with the rapid development of precision medicine, domestic flow cytometry is poised for significant growth opportunities.

Technology Leadership: Full-Spectrum Flow Cytometry Debuts, Breaking Import Monopoly

Since its establishment in 2020, Cenglang BioTech has always taken overcoming the "bottleneck" technologies of flow cytometry as its core mission. Leveraging deep technical expertise, the company has continuously launched domestic brand products including the 2-laser 8-color MateCyte, 3-laser 14-color LongCyte, FongCyte, and the 4-laser FongCyte S, achieving key breakthroughs and becoming a representative enterprise in the domestic flow cytometry field.

In 2025, the CytoStellar series spectral flow cytometer was launched with outstanding performance, achieving a configuration of 5 lasers and over 78 channels. It supports functions such as autofluorescence and similar fluorescence discrimination, breaking through the detection capability of 50 colors in a single tube. This effectively reduces the complexity of experimental design in research analysis, with excellent performance indicators that have significantly elevated the level of domestic flow cytometry innovation.

In 2026, the new research-grade ElaraCyte flow cytometer was introduced to the market, equipped with 4 lasers. It supports ultra-fast high-throughput detection, 80nm small particle detection, 384-well plates, extremely low dead volume, and sample recovery optimization features. Targeting personalized research and biomedical R&D scenarios, it provides systematic optimization solutions in speed, accuracy, stability, and user experience, aiming to become the mainstream model for research flow cytometry.

Striving for Excellence: Deepening Clinical Diagnostics, Providing Disease Auxiliary Diagnosis Solutions

Cenglang BioTech’s flow cytometry six-color lymphocyte subset reagent provides a cost-effective localized solution for clinical immune assessment.

This reagent is deeply integrated with the company’s LongCyte/ClinStellar series flow cytometers. Leveraging the high-sensitivity resolution of the multi-laser, multi-color platform and combined with automated gating templates in the software, it can precisely capture subtle changes in subsets such as CD4⁺ T cells, helping to reduce human errors. It provides reference data for the auxiliary diagnosis and treatment efficacy monitoring of immunodeficiency diseases, autoimmune diseases, and other conditions.

The introduced volumetric absolute counting technology precisely controls sample volume through the instrument’s plunger pump, eliminating the need for expensive counting beads. This not only simplifies the operation process but also significantly reduces per-test consumable costs, achieving extremely high cost-effectiveness while maintaining accuracy, making it suitable for large-scale clinical screening scenarios.

As a domestically developed original reagent, Cenglang has achieved full-process localized R&D and production from antibody labeling and fluorescent dyes to supporting software. It can flexibly adjust antibody combinations based on domestic clinical needs, equipped with a full Chinese-language operating interface and professional technical team, providing convenient services tailored to the characteristics of the local population.

Cenglang BioTech’s detection reagent solutions for cytokines, fine subsets, and platelets are also centered on precision detection, advantaged by cost control, and characterized by localized services, helping to standardize and popularize flow cytometry in the field of disease diagnosis in China.
Market Expansion: Multi-Domain Penetration, Building a Domestic Benchmark

Cenglang BioTech has established a comprehensive product matrix covering diverse application needs from high-end research to frontline clinical adoption.

In 2023, Cenglang reached a strategic cooperation agreement with BD Medical, providing exclusive OEM production of the MateCyte for BD. As a dedicated model for lymphocyte subset detection, it has become a preferred industry solution and a model of collaboration between domestic flow cytometry companies and world-renowned brands.

As of April 2025, Cenglang BioTech has cumulatively delivered 1,000 flow cytometers. Carrying the mission of exploring the unknown, the 1,000th unit was officially delivered to Professor Wang Qiankun’s research group at Shenzhen Bay Laboratory, marking a key milestone in Cenglang BioTech’s market expansion and customer service journey.

Since the launch of Cenglang’s full-spectrum flow cytometer CytoStellar in 2025, it has successively won bids at prestigious institutions including Zhejiang University, Nankai University, Capital Medical University, and the National Institute of Biological Sciences, Beijing (NIBS), serving as strong evidence of Cenglang’s products advancing toward the frontier and reaching new heights.

Entering 2026, Cenglang’s spectral flow cytometry market expansion has been advancing rapidly not only domestically but also achieving sales and deliveries in developed countries in Europe and America. At renowned key laboratories in Europe, expert users have given broad recognition after using the products. It is expected that Cenglang’s high-end spectral flow cytometry will achieve overseas revenue of over RMB 10 million in 2026.

Cenglang will communicate with global users through excellent products, gaining global user acceptance, recognition, and affection for the Cenglang brand, allowing solutions from China to serve global life sciences and clinical diagnostics.

Liu Tiefu, founder of Cenglang BioTech, stated: “We are grateful for the recognition and support from Sunshine Harmony Capital. The Cenglang team has been deeply engaged in the flow cytometry field for nearly 20 years, consistently striving on the path of unique innovation and quality. This financing will provide tremendous support for Cenglang to continue advancing product innovation and market expansion in the research flow cytometry and diagnostic systems fields. We will continue to launch more new and excellent products, create value for the industry and customers, and live up to the trust and support of our investors!”

Sunshine Harmony Capital stated: “Cenglang BioTech is a well-known enterprise in China’s flow cytometry field. Since its establishment, it has continuously broken through technological barriers and introduced innovations. With the launch of its full-spectrum flow cytometer products, it has further broken the import monopoly. Sunshine Harmony Capital has always focused on the domestic substitution of high-end scientific instruments and highly recognizes the Cenglang team’s persistent dedication and perseverance in technology and products. We are optimistic about the company’s future commercialization potential and hope that through this round of financing, we can help Cenglang BioTech achieve greater growth and expand into broader markets.”

Guo Kai, head of StarBridge Capital, stated: “Cenglang BioTech is one of the domestic enterprises that master the core technologies of flow cytometry. The team possesses both profound technical background and rich industrialization experience, maintaining a high-speed development trend since its establishment. We are very pleased to continuously accompany Cenglang BioTech’s growth, assisting it in completing multiple rounds of financing. In the future, we will continue to provide comprehensive capital services for the company, supporting it in breaking through technical bottlenecks, expanding market share, and growing into an important force in the global flow cytometry technology field.”

About Cenglang BioTech

Founded in March 2020, Cenglang BioTech is primarily engaged in the R&D, production, and sales of research and clinical instruments/reagent products in the flow cytometry field. The company is committed to advancing flow cytometry technology to the frontier in research and making it routine in diagnostics, promoting the further popularization of flow cytometry technology, and helping domestic flow cytometry products reach international frontiers. The company has a solid development foundation, having completed two rounds of equity financing historically, with strategic investments from IDG Capital, Lotus Lake Ventures, and Yida Capital, continuously empowering product innovation and scaled development. Current products include clinical instruments MateCyte, LongCyte, ClinStellar (full spectrum), along with supporting reagents for cytokines, lymphocyte subsets, platelets, and HLA-DR. Research-grade products include the FongCyte series, ElaraCyte series, and CytoStellar series flow cytometers.

About Sunshine Harmony Capital

Founded in January 2015, Sunshine Harmony Capital is one of the first private equity fund management companies in China’s insurance industry initiated by insurance funds. After 11 years of development, Sunshine Harmony Capital’s fund management scale has reached RMB 30 billion, with business segments covering fund of funds and direct investment, focusing on healthcare, emerging technology, new consumption, and real estate.

About StarBridge Capital

StarBridge Capital is a Chinese healthcare industry investment bank composed of an experienced industry team, specializing in providing excellent financing services for pharmaceutical and healthcare enterprises. We are dedicated to building bridges between enterprises and capital, comprehensively supporting enterprise development, and providing clients with solutions for various complex transactions including private equity financing, mergers and acquisitions, and restructuring.